Overview
Coherus BioSciences, Inc., based in the United States, operates predominantly in the biotechnology industry, focusing on the development and commercialization of biosimilar therapies. The company aims to challenge the high cost of biologic medications in oncology and autoimmune diseases, offering more affordable patient access through reduced treatment expenses. Key projects include UDENYCA, a biosimilar to Neulasta, which aids in reducing the risk of infection during chemotherapy by boosting white blood cells. Furthermore, Coherus is involved in advancing a pipeline that includes biosimilars of leading drugs such as Humira and Avastin. These initiatives reflect its strategic focus on becoming a significant player in the biosimilar market, potentially transformative for both patient care and health economics.
Quality, Value, Momentum Scores
This card shows the Quality, Value, and Momentum scores for the company
Income Statement: Revenue, Operating Income, Net Income
- The revenue for Coherus Oncology, Inc. as of June 30, 2025 is 272.21 MM.
- The operating income for Coherus Oncology, Inc. as of June 30, 2025 is -88.47 MM.
- The net income for Coherus Oncology, Inc. as of June 30, 2025 is 179.75 MM.
| Period End (TTM) | Revenue (MM) | Operating Income (MM) | Net Income (MM) |
| 2025-06-30 | 272.21 | -88.47 | 179.75 |
| 2025-03-31 | 272.25 | -82.61 | -130.94 |
| 2024-12-31 | 266.96 | -94.37 | 28.51 |
| 2024-09-30 | 174.90 | -166.60 | -0.45 |
| 2024-06-30 | 178.70 | -191.32 | -29.34 |
| 2024-03-31 | 227.12 | -186.24 | -59.29 |
| 2023-12-31 | 257.24 | -193.20 | -237.89 |
| 2023-09-30 | 211.07 | -181.29 | -217.11 |
| 2023-06-30 | 181.93 | -230.63 | -264.12 |
| 2023-03-31 | 183.36 | -240.10 | -271.40 |
| 2022-12-31 | 211.04 | -256.88 | -291.75 |
| 2022-09-30 | 239.06 | -250.13 | -278.61 |
| 2022-06-30 | 276.14 | -197.27 | -230.49 |
| 2022-03-31 | 303.63 | -180.63 | -210.24 |
| 2021-12-31 | 326.55 | -263.86 | -287.10 |
| 2021-09-30 | 363.60 | -202.69 | -231.67 |
| 2021-06-30 | 394.65 | -141.38 | -165.21 |
| 2021-03-31 | 442.68 | -48.70 | -76.28 |
| 2020-12-31 | 475.82 | 156.32 | 132.24 |
| 2020-09-30 | 489.26 | 185.04 | 161.76 |
Income Statement: EPS
- The earnings per share basic for Coherus Oncology, Inc. as of June 30, 2025 is 1.55.
- The earnings per share diluted for Coherus Oncology, Inc. as of June 30, 2025 is 1.55.
| Period End (TTM) | Earnings Per Share Basic | Earnings Per Share Diluted |
| 2025-06-30 | 1.55 | 1.55 |
| 2025-03-31 | -1.14 | -1.13 |
| 2024-12-31 | 0.25 | 0.25 |
| 2024-09-30 | -0.00 | -0.01 |
| 2024-06-30 | -0.27 | -0.27 |
| 2024-03-31 | -0.58 | -0.58 |
| 2023-12-31 | -2.53 | -2.53 |
| 2023-09-30 | -2.53 | -2.53 |
| 2023-06-30 | -3.27 | -3.27 |
| 2023-03-31 | -3.47 | -3.48 |
| 2022-12-31 | -3.76 | -3.76 |
| 2022-09-30 | -3.60 | -3.61 |
| 2022-06-30 | -2.99 | -3.00 |
| 2022-03-31 | -2.75 | -2.75 |
| 2021-12-31 | -3.81 | |
| 2021-09-30 | -3.12 | -3.10 |
| 2021-06-30 | -2.26 | -2.30 |
| 2021-03-31 | -1.06 | -1.02 |
| 2020-12-31 | 1.85 | 1.62 |
| 2020-09-30 | 2.28 | 2.05 |
Cash Flow: Operations, Investing, Financing
- The cash from operating activities for Coherus Oncology, Inc. as of June 30, 2025 is -105.87 MM.
- The cash from investing activities for Coherus Oncology, Inc. as of June 30, 2025 is 445.05 MM.
- The cash from financing activities for Coherus Oncology, Inc. as of June 30, 2025 is -281.72 MM.
| Period End (TTM) | Cash From Operating Activities (MM) | Cash From Investing Activities (MM) | Cash From Financing Activities (MM) |
| 2025-06-30 | -105.87 | 445.05 | -281.72 |
| 2025-03-31 | 0.50 | 10.07 | -188.12 |
| 2024-12-31 | -20.44 | 230.32 | -186.97 |
| 2024-09-30 | -61.98 | 266.07 | -186.84 |
| 2024-06-30 | -54.27 | 316.17 | -175.57 |
| 2024-03-31 | -152.92 | 329.88 | 66.68 |
| 2023-12-31 | -174.88 | 144.64 | 69.60 |
| 2023-09-30 | -261.90 | -20.46 | 75.83 |
| 2023-06-30 | -244.69 | -71.46 | 113.59 |
| 2023-03-31 | -255.81 | -113.71 | 59.98 |
| 2022-12-31 | -241.12 | -166.85 | 54.33 |
| 2022-09-30 | -193.49 | 70.54 | 49.22 |
| 2022-06-30 | -142.69 | 86.98 | 1.45 |
| 2022-03-31 | -92.84 | 111.45 | 47.59 |
| 2021-12-31 | -37.43 | -138.41 | 51.88 |
| 2021-09-30 | 48.01 | -35.84 | 55.91 |
| 2021-06-30 | 81.66 | -35.43 | 58.89 |
| 2021-03-31 | 142.03 | -298.26 | 222.46 |
| 2020-12-31 | 154.15 | -14.40 | 223.95 |
| 2020-09-30 | 138.73 | -230.52 | 219.63 |
Valuation Metrics : PE, PriceToBook, PriceToTBV
- The p/e for Coherus Oncology, Inc. as of June 30, 2025 is -0.65.
- The p/book for Coherus Oncology, Inc. as of June 30, 2025 is -0.46.
- The p/tbv for Coherus Oncology, Inc. as of June 30, 2025 is -0.36.
- P/Book
- The current closing price divided by the book value per share.
- P/TBV
- The current price divided by the tangible book value per share.
| Period End (TTM) | p/e | P/Book | P/TBV |
| 2025-06-30 | -0.65 | -0.46 | -0.36 |
| 2025-03-31 | 3.41 | -0.74 | -0.52 |
| 2024-12-31 | -384.04 | -1.96 | -1.21 |
| 2024-09-30 | -4.12 | -1.44 | -0.87 |
| 2024-06-30 | -3.29 | -2.38 | -1.39 |
| 2024-03-31 | -1.15 | -1.41 | -1.03 |
| 2023-12-31 | -1.71 | -2.78 | -2.05 |
| 2023-09-30 | -1.51 | -2.28 | -2.20 |
| 2023-06-30 | -1.40 | -1.94 | -1.87 |
| 2023-03-31 | -1.87 | -3.96 | |
| 2022-12-31 | -8.01 | -7.54 | |
| 2022-09-30 | -33.04 | -28.55 | |
| 2022-06-30 | 44.68 | 69.67 | |
| 2022-03-31 | -3.47 | 10.21 | 10.59 |
| 2021-12-31 | -5.29 | 9.37 | 9.63 |
| 2021-09-30 | -7.44 | 7.87 | 8.05 |
| 2021-06-30 | |||
| 2021-03-31 | -9.22 | 5.51 | 5.67 |
| 2020-12-31 | 5.27 | 2.48 | 2.51 |
| 2020-09-30 | 4.28 | 2.71 | 2.75 |
Valuation Metrics : EBitToEv, EBit3YrAvgToEv
- The ebit/ev for Coherus Oncology, Inc. as of June 30, 2025 is 0.18.
- The ebit (3y)/ev for Coherus Oncology, Inc. as of June 30, 2025 is -0.30.
| Period End (TTM) | EBIT/EV | EBIT (3y)/EV |
| 2025-06-30 | 0.18 | -0.30 |
| 2025-03-31 | 0.12 | -0.43 |
| 2024-12-31 | -0.00 | -0.52 |
| 2024-09-30 | -0.07 | -0.44 |
| 2024-06-30 | -0.10 | -0.31 |
| 2024-03-31 | -0.37 | -0.42 |
| 2023-12-31 | -0.28 | -0.32 |
| 2023-09-30 | -0.33 | -0.28 |
| 2023-06-30 | -0.32 | -0.27 |
| 2023-03-31 | -0.31 | -0.20 |
| 2022-12-31 | -0.29 | -0.12 |
| 2022-09-30 | -0.26 | -0.11 |
| 2022-06-30 | -0.32 | -0.10 |
| 2022-03-31 | -0.26 | -0.06 |
| 2021-12-31 | -0.18 | -0.00 |
| 2021-09-30 | -0.13 | -0.00 |
| 2021-06-30 | ||
| 2021-03-31 | -0.09 | -0.04 |
| 2020-12-31 | 0.24 | 0.01 |
| 2020-09-30 | 0.21 | -0.02 |
Management Effectiveness
- The roa for Coherus Oncology, Inc. as of June 30, 2025 is -0.19.
- The roic for Coherus Oncology, Inc. as of June 30, 2025 is -1.51.
- The croic for Coherus Oncology, Inc. as of June 30, 2025 is -2.05.
- The ocroic for Coherus Oncology, Inc. as of June 30, 2025 is 0.01.
| Period End (TTM) | ROA | ROE | ROIC | CROIC | OCROIC |
| 2025-06-30 | -0.19 | -1.51 | -2.05 | 0.01 | |
| 2025-03-31 | 0.04 | 0.20 | 0.16 | -0.15 | |
| 2024-12-31 | -0.00 | -0.00 | 0.09 | -0.34 | |
| 2024-09-30 | -0.05 | -0.08 | 0.24 | -0.15 | |
| 2024-06-30 | -0.15 | -0.10 | 0.42 | -0.27 | |
| 2024-03-31 | -0.49 | -0.83 | 0.14 | -0.61 | |
| 2023-12-31 | -0.39 | -0.63 | -0.60 | -0.76 | |
| 2023-09-30 | -0.48 | -0.87 | -0.67 | -0.80 | |
| 2023-06-30 | -0.50 | -0.87 | -0.67 | -0.81 | |
| 2023-03-31 | -0.49 | -23.22 | -0.96 | -1.09 | -0.90 |
| 2022-12-31 | -0.38 | -2.13 | -0.73 | -0.19 | -0.50 |
| 2022-09-30 | -0.31 | -1.76 | -0.83 | -0.22 | -0.58 |
| 2022-06-30 | -0.28 | -1.35 | -0.56 | -0.13 | -0.35 |
| 2022-03-31 | -0.41 | -2.25 | -0.39 | 0.12 | -0.17 |
| 2021-12-31 | -0.28 | -0.82 | -0.56 | -0.24 | 0.09 |
| 2021-09-30 | -0.29 | -0.65 | -0.42 | 0.12 | 0.14 |
| 2021-06-30 | -0.22 | -0.77 | -0.36 | 0.23 | 0.18 |
| 2021-03-31 | -0.16 | -0.48 | -0.14 | 0.12 | 0.26 |
| 2020-12-31 | 0.32 | 1.26 | 0.19 | 0.52 | 0.22 |
| 2020-09-30 | 0.49 | 2.89 | 0.24 | 0.19 | 0.21 |
Gross Margins
- The gross margin for Coherus Oncology, Inc. as of June 30, 2025 is 0.56.
- The net margin for Coherus Oncology, Inc. as of June 30, 2025 is -0.48.
- The operating margin for Coherus Oncology, Inc. as of June 30, 2025 is -0.29.
- Gross Margin
- The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.
- Net Margin
- The Net Margin (aka Profit Margin) is the ratio of revenue left after substracting the Net Income. It is calculated as Net Income / Revenue.
- Operating Margin
- The Operaing Margin is the ratio of revenue left after substracting the Operating Income. It is calculated as Operating Income / Revenue.
| Period End (TTM) | Gross Margin | Net Margin | Operating Margin |
| 2025-06-30 | 0.56 | -0.48 | -0.29 |
| 2025-03-31 | 0.56 | 0.11 | -0.39 |
| 2024-12-31 | 0.45 | -0.00 | -0.39 |
| 2024-09-30 | 0.42 | -0.10 | -0.47 |
| 2024-06-30 | 0.41 | -0.20 | -0.52 |
| 2024-03-31 | 0.38 | -0.92 | -0.77 |
| 2023-12-31 | 0.23 | -1.03 | -0.73 |
| 2023-09-30 | -0.60 | -1.45 | -1.26 |
| 2023-06-30 | -0.51 | -1.45 | -1.26 |
| 2023-03-31 | -0.28 | -1.48 | -1.30 |
| 2022-12-31 | 0.72 | -1.17 | -0.94 |
| 2022-09-30 | 0.74 | -1.17 | -0.94 |
| 2022-06-30 | 0.74 | -0.83 | -0.71 |
| 2022-03-31 | 0.82 | -0.69 | -0.59 |
| 2021-12-31 | 0.46 | -0.88 | -0.81 |
| 2021-09-30 | 0.03 | -0.64 | -0.55 |
| 2021-06-30 | 0.03 | -0.42 | -0.35 |
| 2021-03-31 | 0.21 | -0.17 | -0.11 |
| 2020-12-31 | 0.28 | 0.33 | |
| 2020-09-30 | 0.66 | 0.33 | 0.38 |
Identifiers and Descriptors
| Central Index Key (CIK) | 1512762 |
